Get started
Author

Nuwan Kurukulasuriya

Observed names: N. C. Kurukulasuriya, N. Kurukulasuriya, N.C. Kurukulasuriya, NUWAN C. KURUKULASURIYA, Nuwan C Kurukulasuriya, Nuwan C. Kurukulasuriya
Observed institutions: University of Rome Tor Vergata, Biogen (United States), Merck Serono S.A. (Switzerland), Alexion Pharmaceuticals (United States), Wake Forest University Health Sciences, Wake Forest University
OpenAlex ID: A5043178404
Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study
2016 · Ralf Gold, Douglas L Arnold, et al. · Multiple Sclerosis Journal · 154
PDF
Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience
2015 · Ralf Gold, J. Theodore Phillips, et al. · Neurology and Therapy · 101
PDF
Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing–remitting multiple sclerosis: a systematic review and mixed treatment comparison
2013 · Michael Hutchinson, Robert J. Fox, et al. · Current Medical Research and Opinion · 81
Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing–remitting multiple sclerosis (RRMS)
2014 · Ralf Gold, Gavin Giovannoni, et al. · Multiple Sclerosis Journal · 64
PDF
Oral BG-12 (dimethyl fumarate) for relapsing–remitting multiple sclerosis: a review of DEFINE and CONFIRM
2013 · Eva Havrdova, Michael Hutchinson, et al. · Expert Opinion on Pharmacotherapy · 46
Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate
2015 · John O’Gorman, Heidy K. Russell, et al. · Clinical Therapeutics · 38
Cladribine tablets for relapsing–remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study
2011 · Kottil Rammohan, Gavin Giovannoni, et al. · Multiple Sclerosis and Related Disorders · 38
Does autonomic neuropathy play a role in erythropoietin regulation in non‐proteinuric Type 2 diabetic patients?
2004 · V. Spallone, M. R. Maiello, et al. · Diabetic Medicine · 32
PDF
Cladribine tablets for the treatment of relapsing–remitting multiple sclerosis
2012 · Giancarlo Comi, Hans-Peter Hartung, et al. · Expert Opinion on Pharmacotherapy · 31
Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study
2022 · Grzegorz S. Nowakowski, Dok Hyun Yoon, et al. · Clinical Cancer Research · 28
PDF
Ethanol Influences on Native T-Type Calcium Current in Thalamic Sleep Circuitry
2003 · Jian Mu, W. Breckinridge Carden, et al. · Journal of Pharmacology and Experimental Therapeutics · 27
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma
2023 · Grzegorz S. Nowakowski, Dok Hyun Yoon, et al. · Annals of Hematology · 23
The native T-type calcium current in relay neurons of the primate thalamus
2006 · G.M. Alexander, W.B. Carden, et al. · Neuroscience · 21
Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
2021 · Grzegorz S. Nowakowski, Dok Hyun Yoon, et al. · Blood · 8
Five-Year Follow-up of Delayed-Release Dimethyl Fumarate in RRMS: Integrated Clinical Efficacy Data from the DEFINE, CONFIRM, and ENDORSE Studies (P7.234)
2015 · Amit Bar-Or, Ralf Gold, et al. · Neurology · 8
Cortical feedback to the thalamus is selectively enhanced by nitric oxide
2006 · G.M. Alexander, N.C. Kurukulasuriya, et al. · Neuroscience · 8
Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience (P7.238)
2015 · Jie Li, Ralf Gold, et al. · Neurology · 6
Lymphocyte Count Reductions in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Treated with Delayed-Release Dimethyl Fumarate: An Integrated Analysis of the Placebo-Controlled Studies (P3.179)
2014 · Robert Fox, Ralf Gold, et al. · Neurology · 6
Long-term Efficacy of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with RRMS: An Integrated Analysis of DEFINE, CONFIRM, and ENDORSE (P7.227)
2015 · Ralf Gold, Gavin Giovannoni, et al. · Neurology · 5
BG-12 (dimethyl fumarate) and pregnancy: Preclinical studies and pregnancy outcomes reported during the clinical development program
2013 · R. Gold, J.T. Phillips, et al. · Journal of the Neurological Sciences · 5
BG-12 (Dimethyl Fumarate) Treatment for Relapsing–Remitting Multiple Sclerosis (RRMS) Increases the Proportion of Patients Free of Measured Clinical and Neuroradiologic Disease Activity in the Phase 3 Studies (P07.106)
2013 · Eva Havrdova, Ralf Gold, et al. · Neurology · 4
Transneuronal retrograde transport of attenuated pseudorabies viruses within central visual pathways
2001 · RODNEY J. MOORE, SHERRY VINSANT, et al. · Visual Neuroscience · 4
Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma
2023 · Grzegorz S. Nowakowski, Dok Hyun Yoon, et al. · Annals of Hematology · 3
PDF
Five-Year Follow-up of Delayed-Release Dimethyl Fumarate in Relapsing-Remitting Multiple Sclerosis: MRI Outcomes from DEFINE, CONFIRM, and ENDORSE (P7.262)
2015 · Tarek Yousry, Douglas Arnold, et al. · Neurology · 3
Efficacy of Delayed-Release Dimethyl Fumarate for RRMS in Prior Interferon Users in the DEFINE and CONFIRM Studies (P7.231)
2015 · Oscar Fernandez, Gavin Giovannoni, et al. · Neurology · 3
Works count: 67
Citation count: 766
H-index: 13
I10-index: 13
Year
Topic
Type